The businesses entered into an agreement Nov. 14 to combine, and the resulting company will have an estimated pro-forma enterprise value of $482 million. The transaction is expected to close in early 2022. Chris Walsh, Accelus CEO and co-founder, will become CEO of the combined company. He has 25 years of experience in the medtech industry with past roles at Stryker and NuVasive. CHP Merger Corp. is a special purpose acquisition vehicle formed by an affiliate of private equity firm Concord Health Partners.